Skip to content

Safety and Efficacy of Endovascular Therapy in Patients with Cognitive Impairment Combined with Intracranial Venous Thrombosis

Safety and Efficacy of Endovascular Therapy in Patients with Cognitive Impairment Combined with Intracranial Venous Thrombosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114645
Enrollment
Unknown
Registered
2025-12-16
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment Combined with Intracranial Venous Thrombosis

Interventions

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age over 18 years old, gender is not limited; 2. Inpatients diagnosed with intracranial venous sinus thrombosis according to the "Chinese Guidelines for the Diagnosis and Treatment of Intracranial Venous Thrombosis 2019" or Diagnosis and Management of Cerebral Venous Thrombosis: A Scientific Statement from the American Heart Association; 3. Cognitive impairment assessed as neuropsychological assessment: MoCA<=25 (adjusted for education level) or MMSE<=29; 4.Patients and their families voluntarily joined this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who have been diagnosed with cognitive impairment or decline caused by the following diseases: central nervous system demyelinating disease, tumor, hydrocephalus, trauma, syphilis, AIDS, Creutzfeldt-Jakob disease, severe depression, VitB12 deficiency, and hypothyroidism; 2. Patients with acute myocardial infarction, severe coronary arteriosclerosis, and bleeding tendency (such as subarachnoid hemorrhage, cerebral hemorrhage, gastrointestinal hemorrhage, extensive retinal hemorrhage, subdural hematoma, epidural hematoma, etc.); 3. Those who have contraindications to anticoagulation or endovascular therapy; 4. Participating in other clinical drug trials; 5. Expected survival < 6 months; 6.Other conditions deemed by the investigator to be inappropriate for inclusion.

Design outcomes

Primary

MeasureTime frame
ADAS-Cog;

Countries

China

Contacts

Public ContactHu Bo

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

hubo@mail.hust.edu.cn+86 137 0711 4863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026